Pre-Test Addressing Menopausal Symptoms in Primary Care with Newer Treatment Options Pre-Test Which of the following statements regarding the impact of menopause is TRUE? Depression is more prevalent among premenopausal women than perimenopausal women On average, postmenopausal females have lower fasting blood glucose levels than premenopausal women Up to 84% of postmenopausal women are affected by urogenital syndrome of menopause (UGM) Vasomotor symptoms (VMS) do not demonstrate racial and ethnic variations Unsure Larissa, your 57-year-old female patient, is experiencing severe vasomotor symptoms (VMS). Menses stopped 15 months ago, and she has an intact uterus. She has no depressive symptoms, and no history of breast cancer, CAD, VTE, liver or kidney disease. She is taking allopurinol, a CYP1A2 inhibitor, to prevent recurrence of gout. Which of the following options would you prescribe, based on the NAMS guidelines? An insertable 10-μg estradiol vaginal tablet Bioidentical 17β-estradiol combined with progesterone Neurokinin receptor inhibitor Ospemifene Unsure Which of the following approved agents blocks the neurokinin-3 receptors that play a role in regulating temperature? 17β-estradiol Bazedoxifene Fezolinetant Paroxetine Unsure Severe VMS are associated with increased risks for which of the following? Aneurysm and dyslipidemia Depression and diabetes Icosapent ethyl Obesity and sleep apnea Osteoarthritis and sarcopenia Unsure Please rate your ability to implement newer FDA-approved options in to routine care for the management of symptoms related to menopause. Excellent Very good Good Fair Poor
